Furthermore, targeting pan-CXCL12 by olaptesed pegol (ola-PEG), which neutralizes CXCL12 irrespective of the isoform, prevented MM progression in a murine model [8], while a recent phase IIa clinical trial showed that patients with relapsed/refractory MM respond favorably to a combination of bortezomib or dexamethasone with ola-PEG [53]. Here, CXCL12 is linked to Miyoshi myopathy.